Terms ending in 2027
Every in-force patent on GlaxoSmithKline LLC's record whose computed term ends in 2027, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 7,972,994 | Methods for Synthesis of Encoded Libraries In force · High confidence | GlaxoSmithKline, LLC | In force | High confidence | |
| US 9,901,479 | External Nasal Dilator and Methods In force · Medium confidence | Foundation Consumer Brands, LLC | In force | Medium confidence | |
| US 8,158,665 | Farnesoid X Receptor Agonists In force · High confidence | GlaxoSmithKline LLC | In force | High confidence | |
| US 7,838,540 | 3-Aminocarbonyl, 6-Phenyl Substituted PYRIDINE-1-Oxides as P38 Kinase Inhibitors In force · High confidence | GlaxoSmithKline LLC | In force | High confidence | |
| US 8,557,834 | Prolyl Hydroxylase Inhibitors In force · High confidence | GlaxoSmithKline LLC | In force | High confidence | |
| US 8,815,884 | Prolyl Hydroxylase Inhibitors In force · Medium confidence | GlaxoSmithKline LLC | In force | Medium confidence | |
| US 10,035,779 | Prolyl Hydroxylase Inhibitors In force · Medium confidence | GlaxoSmithKline, LLC | In force | Medium confidence | |
| US 10,336,711 | Prolyl Hydroxylase Inhibitors In force · Medium confidence | GlaxoSmithKline, LLC | In force | Medium confidence | |
| US 11,643,397 | Prolyl Hydroxylase Inhibitors In force · Medium confidence | GlaxoSmithKline LLC | In force | Medium confidence | |
| US 8,138,338 | Aurora Kinase Inhibitors from an Encoded Small Molecule Library In force · High confidence | GlaxoSmithKline LLC | In force | High confidence | |
| 7 more term ends in 2027 · Pro | |||||
10 of 17 patents shown. Soonest term end first, then patent number.
Pro members see all 17, all of them expiring within the 18 months from Nov 20, 2026.
14 of these are in force and held by GlaxoSmithKline LLC.
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.